Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
Branch retinal vein occlusion (BRVO) Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each sufferer. There are some cases where a person can ...


Retinal Vein Occlusions industry forecast to 2025 examined in new market research report
Facts of Week
Retinal vein occlusions occurs when there is a blockage of veins carrying blood with needed oxygen and nutrients to the nerve cells in the retina. Retinal vein is divided into two different types such as; central retinal vein occlusion (CRVO) and ...

and more »

MD Magazine

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure
MD Magazine
The patient population included 18 males and 24 females with a mean age of 57.81 years (± 14.11). There were 13 eyes with diabetes mellitus (31%), and 5 eyes with a history of cataract surgery (11%). Eleven patients had at least an eye with branch ...


Worldwide Retinal Vein Occlusion Market | Expected to grow at a CAGR of 11.2% during the forecast period 2017-2023
Medgadget (blog)
Retinal vein occlusion is categorized on the basis of the location of occlusion; they are branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Retinal vein occlusion is the retinal vascular disease and normally affects older ...

and more »

Investor's Business Daily

Genentech (RHHBY) Says Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody ...
StreetInsider.com
Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization ...
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With ...Business Wire (press release)

all 8 news articles »

WhaTech

Pharmapoint: Macular edema market forecast to 2026 insights shared in detailed report
WhaTech
... which is the area of the retina that is responsible for central vision. - Advertising -. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause ...

and more »

Gacad: When it rains, it pours
Sun.Star
The retina is the light-sensitive tissue at the back of the eye and the macula is the part of the retina responsible for sharp, straight-ahead vision. Fluid buildup causes the macula to swell and thicken, which distorts vision. Arteries and veins carry ...


Top 10 Ophthalmic Suspension Market Players Worldwide Revenue, Size and Shares by 2023
Quebec Daily Examiner
Pune, India — 02/06/2018 — Ophthalmic Suspension (eye drops) are medication used to treat eye redness, inflammation, irritation, and others. Generally, ophthalmic suspension is prepared keeping in mind the following properties like viscosity ...

and more »

Macular Edema Market 2018 Global Analysis, Opportunities and Forecast to 2026
Industry Today (press release)
... of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause of ...

and more »

Retinal Vein Occlusion Therapeutics Market Growth and Forecast 2015-2021
MilTech
Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after diabetic retinopathy. The RVO is mainly of two types based on the anatomy of the vein occlusion. The ...

and more »

Macular Edema Pharmaceutical and Healthcare Analysis Information
Industry Today (press release)
... of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause of ...

and more »

Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


ModernMedicine

Algorithms provide guidance for managing RVO-related macular edema
ModernMedicine
... treatment for macular edema, secondary to retinal vein occlusion (RVO), and indicate that when patients respond, it may be possible to reduce the frequency of injections, particularly after one year. However, more research is needed to better ...


Widening use of dexamethasone implant for the treatment of macular edema
Dove Medical Press
Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious ...


Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
We postulate that RVO and AMI may be associated because the changes in retinal vessels may somehow imply that changes have also occurred in coronary vessels.” The researchers further divided the RVO group into individuals with central retinal vein ...


PR Newswire (press release)

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of ...
PR Newswire (press release)
Retinal vein occlusion is the second most common cause of reduced vision due to a retinal vascular disorder; the most common cause is diabetic retinopathy.ix,i It is defined as obstruction of a retinal vein, which causes haemorrhage in the retina. This ...

and more »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal ...


PharmaPoint: Global Macular Edema Market Analysis, Growth, Opportunity and Forecast to 2026
satPRnews (press release)
... of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause of ...

and more »

Bel Marra Health

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment
Bel Marra Health
Branch retinal artery occlusion (BRAO): Occurs suddenly and is typically painless. Vision loss can be appreciated as a loss of the peripheral vision, with some cases also losing central vision. Vein occlusion is usually caused by a clot or plaque that ...


Medscape

Should We WAVE Goodbye to Laser?
Medscape
Secondary outcome measures included mean changes in central retinal thickness and safety analyses. The investigators found no additional benefits associated with TRP among primary or secondary outcome measures. There were no significant differences ...


Laser retains limited role for management of RVO-related ME
ModernMedicine
In the current era where pharmacologic therapy is the preferred treatment for macular edema secondary to retinal vein occlusion (RVO), there is still a role for laser, according to Francesco Bandello, MD. “Laser photocoagulation–especially subthreshold ...


MD Magazine (blog)

Ranibizumab Outperforms Aflibercept in Efficacy, Durability
MD Magazine (blog)
Additionally, the 5-year LUMINOUS study, which assessed the real-world efficacy of ranibizumab in more than 30000 patients with diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion and myopic choroidal ...

and more »

Business Wire (press release)

Vital Art and Science Announces License Agreement with Genentech for Its mVT® Service
Business Wire (press release)
The mVT® Service is currently commercially available to retina specialists for patients with maculopathy, including dry and wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, macular pucker, macular hole, retinal vein ...

and more »

Reports Healthcare

What is an Eye Stroke? Causes, Symptoms and Treatment
Reports Healthcare
Consequently, the retina loses its blood supply and all the fluid and blood starts flooding the retina which results in swelling. At this point, medical attention is mandatory since there is a risk of loss of eyesight and permanent blindness. There are ...


Science Daily

Surgical eye robot performs precision-injection in patient with retinal vein occlusion
Science Daily
Researchers at University Hospitals Leuven and KU Leuven are studying retinal vein cannulation (RVC), a revolutionary treatment that addresses the cause of retinal vein occlusion by removing the blood clot in the retinal vein. RVC is a promising method ...

and more »

Medscape

Despite Significantly Different Pricing, Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
Medscape
The goal of the multicenter clinical SCORE2 trial was to establish the safety and efficacy of bevacizumab compared with aflibercept in the treatment of macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO ...


MD Magazine

IRIS Registry Finds New AMD, DME Population Data
MD Magazine
Another study of randomized, controlled trials has found that previous reports of 10% retinal disease patients to receive anti-VEGF therapy experience potentially damaging pressure rise inside the eye may be a misconeption. Researchers reviewed 23,776 ...
World's Largest Clinical Specialty Database Yields Critical Insights to Advance Ophthalmic Patient CarePR Newswire (press release)

all 4 news articles »

Nasdaq

Regeneron (REGN) Stock on Fire: What's Behind the Surge?
Nasdaq
The drug is also approved for macular edema following retinal vein occlusion, which includes macular edema post central retinal vein occlusion as well as macular edema following branch retinal vein occlusion. Meanwhile, Regeneron is working on ...

and more »

PMLiVE

NICE backs Bayer's Eylea as first-line BRVO treatment
PMLiVE
Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein occlusion (BRVO). NICE approved the anti-vascular endothelial growth factor (anti-VEGF) treatment as ...

and more »

Eye stroke: Symptoms, risks, and treatment
BusinessGhana
One of these critical tissues is the retina, which is at the back of the eye. The retina plays a crucial role in sending visual signals to the brain, and it contains small and large arteries and veins that move blood to and from the heart. This blood ...

» Load more